Leukodystrophy and Leukoencephalopathy, Adult Onset Panel
Use
This test is intended for individuals with relevant clinical features who have a clinical or suspected diagnosis of adult-onset leukodystrophy or leukoencephalopathy. It is also suitable for individuals with characteristic adult-onset white matter abnormalities observed on neuroimaging, which are conditions associated with disorders in the genetic makeup affecting the brain's white matter.
Special Instructions
Not provided.
Limitations
The test's effectiveness relies on comprehensive clinical information provided by the ordering physician, which directly correlates with the ability to interpret variants. The prevention genetics tests have not been cleared or approved by the US FDA, which may affect the validation and applicability of the results in specific clinical settings.
New York Approved
Methodology
NGS (CGP)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided